CurrentEndo
Get Weekly

Diabetes journalCurrentEndo coverage

Diabetes, Obesity and Metabolism

What CurrentEndo has captured from this journal. The coverage figures describe CurrentEndo's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentEndo holds 2,200 Briefs from Diabetes, Obesity and Metabolism, most often cohort studies and randomized controlled trials.

Recent
146 Briefs
past 90 days
Archive
2,200 Briefs
research published from January 2023 to today
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 2,200 Briefs CurrentEndo has covered from Diabetes Obes Metab, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Association Between Orforglipron and Blood Pressure in Adults With Obesity With or Without Type 2 Diabetes: Post Hoc Analyses From ATTAIN‐1 and ATTAIN‐2 Trials

    Secondary analysisObesity

  2. Diabetes Obes Metab

    Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

    Research articleObesity

  3. Diabetes Obes Metab

    Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters

    Cohort studyObesity

  4. Diabetes Obes Metab

    Birthweight and Glucose Tolerance Status Are Associated With Organ Sizes in Older Adults

    Cohort studyT2D & other

  5. Diabetes Obes Metab

    Development and Validation of 10‐Year Prediction Models for Cardiovascular, Kidney and Metabolic Events Among Chinese Patients With Prediabetes in Hong Kong

    Diagnostic or prognostic studyT2D & other

  6. Diabetes Obes Metab

    Diabetes Type and Perinatal Adverse Outcomes Among Women in Pregnancy and Neonates in Japan: A Cohort Study Using a Large‐Scale Database

    Cohort studyDiabetes in pregnancy

  7. Diabetes Obes Metab

    Diabetic Ketoacidosis: Systematic Review and Meta‐Analysis

    Meta-analysisT1D

  8. Diabetes Obes Metab

    Effectiveness of GLP ‐1 RAs and SGLT ‐2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial

    Cohort studyT2D & other

  9. Diabetes Obes Metab

    Global Trends and Exposure Profiling of Early‐Onset Type 2 Diabetes: An Ecological Analysis Using Machine Learning

    Diagnostic or prognostic studyT2D & other

  10. Diabetes Obes Metab

    GLP ‐1 Receptor Agonists Use in Patients With Prior Psychotropic Treatment: A Nationwide Cohort Study

    Cohort studyT2D & other

  11. Diabetes Obes Metab

    Longitudinal Associations of Changes in Body Mass Index and Waist‐to‐Height Ratio With Cardiometabolic Risk Factors: Sex‐Specific Analyses in UK Biobank

    Cohort studyObesity

  12. Diabetes Obes Metab

    Screening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps

    Meta-analysisObesity

  13. Diabetes Obes Metab

    Clinical Characteristics, Effectiveness and Safety Outcomes in Chinese Patients With Chronic Kidney Disease and Type 2 Diabetes Who Initiated Finerenone: A Retrospective Real‐World Cohort Study From the FOUNTAIN Platform

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    Effects of GLP ‐1 Receptor Agonists on Hyperuricemia, Serum Uric Acid and Gout: A Systematic Review and Meta‐Analysis

    Meta-analysisT2D & other

  15. Diabetes Obes Metab

    Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT ‐1 Randomized Controlled Trial

    Secondary analysisT2D & other

  16. Diabetes Obes Metab

    Differences in the Glucose Management Indicator Between Continuous Glucose Monitoring Systems

    Cohort studyTechnology

  17. Diabetes Obes Metab

    Metformin and Severe Post‐ COVID ‐19 Outcomes Among Individuals With Diabetes Mellitus

    Cohort studyT2D & other

  18. Diabetes Obes Metab

    Effects of a Low‐Carbohydrate Diet Combined With Exercise on HbA1c in Adults With Type 2 Diabetes: A Bayesian Multilevel Network and Dose–Response Meta‐Analysis

    Meta-analysisT2D & other

  19. Diabetes Obes Metab

    Plasma Proteomic Signatures for Early Risk Stratification Across Cardiovascular‐Kidney‐Metabolic Stages 0–2

    Cohort study

  20. Diabetes Obes Metab

    Sleep Patterns During Pregnancy, Genetic Susceptibility and Progression From Gestational Diabetes Mellitus to Postpartum Glucose Intolerance: A Prospective Cohort Study

    Cohort studyDiabetes in pregnancy

  21. Diabetes Obes Metab

    Carbohydrate Intake Variability, Weight Change and Type 2 Diabetes Risk: A Prospective Cohort Study

    Cohort studyT2D & other

  22. Diabetes Obes Metab

    Contemporary Initial Glucose‐Lowering Strategies for Type 2 Diabetes: A Systematic Review and Bayesian Network Meta‐Analysis

    Meta-analysisT2D & other

  23. Diabetes Obes Metab

    Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

    Meta-analysisObesity

  24. Diabetes Obes Metab

    Genetically Proxied GIP ‐ GIPR Pathway Perturbation and Fracture Risk

    Research articleBone & mineral

  25. Diabetes Obes Metab

    Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

    Mechanistic studyT1D

  26. Diabetes Obes Metab

    Metformin Use Is Associated With Better Cognitive Performance in Older Adults With Type 2 Diabetes: Exploratory Analysis of Vitamin B12 and Methylmalonic Acid Pathways in NHANES 2011–2014

    Cross-sectional studyT2D & other

  27. Diabetes Obes Metab

    Real‐World Burden of Diabetic Ketoacidosis in Type 1 Diabetes in the French SFDT1 Cohort: The SFDT1 ‐ DKA Study

    Cohort studyT1D

  28. Diabetes Obes Metab

    Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series

    Cohort studyObesity

  29. Diabetes Obes Metab

    Body Weight Change and Dementia Risk in Young and Middle‐Aged Adults With Type 2 Diabetes and Depression: A Nationwide Cohort Study

    Cohort studyT2D & other

  30. Diabetes Obes Metab

    Cardiovascular Classification in Middle‐Aged and Elderly CKD Patients: A Machine Learning Approach in China and the United States

    Cross-sectional study

  31. Diabetes Obes Metab

    Effectiveness of Adding GLP ‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

    Cohort study

  32. Diabetes Obes Metab

    Risk Stratification by eGFR < 45 mL /min/1.73 m 2 for All‐Cause Mortality in Patients With Diabetic Foot Ulcer: A Multidisciplinary Retrospective Cohort Study

    Cohort studyComplications

  33. Diabetes Obes Metab

    Evaluating the Effectiveness of the Reducing Weight With Intensive Dietary Support ( REWIND ) Programme on Type 2 Diabetes Remission

    Cohort studyT2D & other

  34. Diabetes Obes Metab

    Association of Phenotypic Age Acceleration With Pancreatic Fat Percentage in a UK Biobank Imaging Population

    Cross-sectional studyLipids & liver

  35. Diabetes Obes Metab

    Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

    Cohort studyT2D & other

  36. Diabetes Obes Metab

    Real‐World Adverse Event Reporting Patterns of Tirzepatide Versus Semaglutide: A Stratified Study of General and Healthcare Professional Cohorts in FAERS

    Research articleObesity

  37. Diabetes Obes Metab

    Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP

    Secondary analysisObesity

  38. Diabetes Obes Metab

    Multimodal Exploratory Analysis of Persistent Diabetic Macular Edema: Integrating Aqueous Humour Metabolomics, Clinical and OCT Features

    Case-control studyComplications

  39. Diabetes Obes Metab

    Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist

    Research articleObesity

  40. Diabetes Obes Metab

    Sex and Socioeconomic Differences in the Initiation of SGLT2 Inhibitors and GLP ‐1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Nationwide Cohort Study

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing the 40 most recently published